How to Buy Wanbury Ltd Shares?
You can easily buy the stocks/shares of Wanbury Ltd (WANBURY) on Tickertape or through broker platform by opening a Demat & Trading account onlineWhat is the Share Price of Wanbury Ltd?
The stock prices are volatile and keep changing through the day depending upon various factors and market conditions. The Share price of WANBURY as on 15th May 2025 is ₹282.33What is the return on Wanbury Ltd share?
The past returns of Wanbury Ltd (WANBURY) share are- Past 1 week: N/A
- Past 1 month: -92.77
- Past 3 months: 48.36
- Past 6 months: 6.39
- Past 1 year: 98.37
- Past 3 years: 400.72
- Past 5 years: 1496.93
What is the Dividend yield % on Wanbury Ltd share?
The current dividend yield of Wanbury Ltd (WANBURY) is N/AWhat is the Market Cap of Wanbury Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Wanbury Ltd (WANBURY) is ₹1021.74Cr as of 15th May 2025What is the 52 Week High and Low of Wanbury Ltd?
The 52-week high and low of Wanbury Ltd (WANBURY) is ₹329.70 and ₹152.81.What is the PE and PB ratio of Wanbury Ltd?
The P/E (price-to-earnings) and P/B (price-to-book) ratios of Wanbury Ltd are 33.47 and 36.56 respectively.Which sector does Wanbury Ltd belong to?
Wanbury Ltd (WANBURY) belongs to the Health Care sector & Pharmaceuticals sub-sector.What are the peers or stocks similar to Wanbury Ltd?
The peers or stocks similar to Wanbury Ltd are: and many others.Can't decide whether or not to buy Wanbury Ltd?
Worry no more! Login to Tickertape and check out Wanbury Ltd (WANBURY) scorecard & all the relevant insights today5. Test Stocks FAQ What is the 52 Week High and Low of Wanbury Ltd?
The 52-week high and low of Wanbury Ltd (WANBURY) is ₹329.70 and ₹152.81.1. Test Stocks FAQ for Wanbury Ltd Shares?
You can easily buy the stocks/shares of Wanbury Ltd (WANBURY) on Tickertape or through broker platform by opening a Google & Trading account online3. Test Stocks FAQ What is the Share Price of Wanbury Ltd?
The stock prices are volatile and keep changing through the day depending upon various factors and market conditions. The Share price of WANBURY as on 15th May 2025 is ₹282.33
Wanbury Ltd
WANBURY Share Price
282.334.54% (+12.26)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
WANBURY Performance & Key Metrics
WANBURY Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 33.46 | 36.56 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.21 | 6.66 | 0.83% |
WANBURY Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
WANBURY Company Profile
Wanbury Limited is a pharmaceutical company which offers active pharmaceutical ingredient in over 70 countries.
SUNPHARMA
PE Ratio
37.00
37.00
1Y Return
11.72%
11.72%
Buy Reco %
89.19
89.19
CIPLA
PE Ratio
23.03
23.03
1Y Return
2.55%
2.55%
Buy Reco %
71.05
71.05
DRREDDY
PE Ratio
20.02
20.02
1Y Return
11.76%
11.76%
Buy Reco %
82.05
82.05
TORNTPHARM
PE Ratio
57.53
57.53
1Y Return
13.13%
13.13%
Buy Reco %
67.74
67.74
MANKIND
PE Ratio
49.29
49.29
1Y Return
6.30%
6.30%
Buy Reco %
—
—
WANBURY Sentiment Analysis
WANBURY Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
WANBURY Stock Summary · January 2025
Company is navigating a complex landscape characterized by declining market share in deposits, challenges in meeting Priority Sector Lending (PSL) obligations, and fluctuations in current account flows. Despite these hurdles, the bank is focusing on enhancing customer engagement and service delivery to drive deposit growth, with recent monthly inflows showing a positive trend. The management emphasizes a strategic approach to maintaining profitability over aggressive expansion, particularly in light of competitive pressures and a tight liquidity environment. Efforts to improve operational efficiencies through digitization and a commitment to stable cost management are underway, alongside a proactive strategy to reduce borrowings and strengthen the balance sheet. Overall, while facing short-term challenges, the bank remains optimistic about future performance and is committed to achieving sustainable growth through strategic investments and improved customer outreach.
WANBURY Stock Growth Drivers
WANBURY Stock Growth Drivers
1Focus on Sustainable Growth
Company is prioritizing profitable growth over mere expansion, emphasizing a strategy that encourages ground-level teams
WANBURY Stock Challenges
WANBURY Stock Challenges
2Deposit Growth Shortfalls
The company has experienced deposit growth that has not met expectations, attributed to seasonal trends
Loan Growth Concerns
There is uncertainty regarding the company's loan deposit ratio (LDR) and its implications for loan
WANBURY Forecast
What are forecasts?
What are forecasts?
Forecasting uses historical data as inputs to make informed predictive estimates determining the direction of future trends. Price, revenue & earnings forecasts represent where the stock level, business prospects and profits are potentially expected to be at the end of the forecast period
WANBURY Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
WANBURY
WANBURY
Income
Balance Sheet
Cash Flow
Annual Normal View
WANBURY Income Statement
WANBURY Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 523.49 | 447.80 | 400.70 | 451.23 | 394.92 | 589.07 | 500.56 | 604.20 | 603.01 | 603.00 | ||||||||||
Raw Materials | 191.12 | 166.40 | 201.26 | 169.75 | 228.53 | 325.07 | 274.31 | 306.52 | 523.20 | 523.19 | ||||||||||
| Power & Fuel Cost | 18.74 | 15.26 | 14.46 | 15.38 | 17.13 | 18.41 | 20.59 | 24.58 | ||||||||||||
| Employee Cost | 87.77 | 87.32 | 75.89 | 67.48 | 64.15 | 74.81 | 81.00 | 86.92 | ||||||||||||
| Selling & Administrative Expenses | 76.62 | 64.45 | 63.70 | 55.36 | 45.49 | 55.13 | 59.28 | 76.53 | ||||||||||||
| Operating & Other expenses | 41.03 | 105.59 | 20.52 | 36.04 | 19.20 | 2.44 | 41.89 | 11.10 | ||||||||||||
EBITDA | 108.21 | 8.78 | 24.87 | 107.22 | 20.42 | 113.21 | 23.49 | 98.55 | 79.81 | 79.81 | ||||||||||
| Depreciation/Amortization | 10.32 | 10.30 | 9.97 | 9.68 | 9.75 | 11.45 | 12.38 | 13.03 | 13.31 | 13.30 | ||||||||||
| PBIT | 97.89 | -1.52 | 14.90 | 97.54 | 10.67 | 101.76 | 11.11 | 85.52 | 66.50 | 66.51 | ||||||||||
| Interest & Other Items | 35.51 | 30.86 | 39.88 | 32.87 | 23.07 | 20.61 | 21.39 | 29.18 | 36.95 | 36.95 | ||||||||||
| PBT | 62.38 | -32.38 | -24.98 | 64.67 | -12.40 | 81.15 | -10.28 | 56.34 | 29.55 | 29.56 | ||||||||||
| Taxes & Other Items | 0.39 | -0.38 | -0.14 | 0.21 | 0.20 | -0.35 | 0.11 | 0.38 | -0.98 | -0.98 | ||||||||||
| Net Income | 61.99 | -32.00 | -24.84 | 64.46 | -12.60 | 81.50 | -10.39 | 55.96 | 30.53 | 30.54 | ||||||||||
| EPS | 28.71 | -13.63 | -10.47 | 26.46 | -5.04 | 28.26 | -3.18 | 17.10 | 9.32 | 9.33 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
WANBURY Company Updates
WANBURY Stock Peers
What are peers and why compare against them?
What are peers and why compare against them?
A stock's peers are companies which have similar business interests, operations and belong to the same industry sector. Comparing various metrics against peers can give valuable insights on whether the company's stock is over/under-valued and the company's growth outlook vs the industry as a whole
WANBURY Past Performance & Peer Comparison
WANBURY Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Wanbury Ltd | 33.47 | 36.56 | — |
| Sun Pharmaceutical Industries Ltd | 37.00 | 6.03 | 0.95% |
| Cipla Ltd | 23.03 | 4.53 | 1.06% |
| Dr Reddy's Laboratories Ltd | 20.02 | 4.01 | 0.59% |
WANBURY Stock Price Comparison
Compare WANBURY with any stock or ETFCompare WANBURY with any stock or ETF
WANBURY
WANBURY Holdings
WANBURY Shareholdings
What are shareholdings?
What are shareholdings?
Apart from retail investors, a company’s shares are held by promoters, foreign & domestic institutions (large investors) and mutual funds. Promoters are the ship captains and control the company’s direction. Along with institutional and mutual fund holdings, a change in their holdings can indicate performance outlook for the stock
WANBURY Promoter Holdings Trend
WANBURY Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
High Pledged Promoter Holding
Lower pledged promoter holdings is considered better
A significant proportion of promoter holdings is pledged
WANBURY Institutional Holdings Trend
WANBURY Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
WANBURY Shareholding Pattern
WANBURY Shareholding Pattern
WANBURY Shareholding History
WANBURY Shareholding History
Foreign Institutions
smallcases containing WANBURY stock
smallcases containing WANBURY stock
Looks like this stock is not in any smallcase yet.
WANBURY Events
WANBURY Events
WANBURY Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
WANBURY has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
What are dividends?
What are dividends?
Dividends are a portion of earnings that a company distributes to all its shareholders every year. Dividend return is one of the most important things to be considered while investing for long term. It’s the additional return on top of what investors earn through price appreciation
WANBURY Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
WANBURY has not given any dividends in last 5 years
WANBURY Upcoming Dividends
WANBURY Upcoming Dividends
No upcoming dividends are available
WANBURY Past Dividends
WANBURY Past Dividends
Cash Dividend
Ex DateEx DateJul 29, 2010
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Jul 29, 2010
WANBURY Stock News & Opinions
WANBURY Stock News & Opinions
Articles & Videos
Spotlight
Wanbury's Patalganga facility receives GMP certification from ANVISA
Earlier this month, on 12 May 2025, the company had also received GMP approval from ANVISA for its Tanuku site in Andhra Pradesh. The certification for the Patalganga site follows ANVISA's review of the inspection report of U.S. FDA, along with other documents submitted by the company. Based on the evaluation, ANVISA granted the GMP certification, confirming the facility's compliance with Brazilian regulatory standards. With this certificate, now both the API manufacturing sites of Wanbury continue to be compliant per ANVISA' s rules & regulations. Wanbury is a pharmaceutical company with a presence in the global API market and domestic branded formulations. The company's consolidated net profit declined 88.12% to Rs 1.22 crore as revenues fell by 8.28% to Rs 133.45 crore in Q3 FY25 as compared with Q3 FY24. The counter declined 1.74% to Rs 299.35 on the BSE. Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Earnings
Wanbury consolidated net profit declines 39.76% in the March 2025 quarter
Net profit of Wanbury declined 39.76% to Rs 20.26 crore in the quarter ended March 2025 as against Rs 33.63 crore during the previous quarter ended March 2024. Sales rose 23.38% to Rs 172.00 crore in the quarter ended March 2025 as against Rs 139.41 crore during the previous quarter ended March 2024. For the full year,net profit declined 45.44% to Rs 30.53 crore in the year ended March 2025 as against Rs 55.96 crore during the previous year ended March 2024. Sales rose 4.14% to Rs 599.51 crore in the year ended March 2025 as against Rs 575.65 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales172.00139.41 23 599.51575.65 4 OPM %17.2313.03 -12.7312.16 - PBDT22.4311.63 93 42.8643.81 -2 PBT19.058.35 128 29.5530.78 -4 NP20.2633.63 -40 30.5355.96 -45 Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Wanbury standalone net profit rises 150.74% in the March 2025 quarter
Net profit of Wanbury rose 150.74% to Rs 20.26 crore in the quarter ended March 2025 as against Rs 8.08 crore during the previous quarter ended March 2024. Sales rose 23.38% to Rs 172.00 crore in the quarter ended March 2025 as against Rs 139.41 crore during the previous quarter ended March 2024. For the full year,net profit rose 0.43% to Rs 30.53 crore in the year ended March 2025 as against Rs 30.40 crore during the previous year ended March 2024. Sales rose 4.14% to Rs 599.51 crore in the year ended March 2025 as against Rs 575.65 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales172.00139.41 23 599.51575.65 4 OPM %17.2313.03 -12.7312.16 - PBDT22.4311.63 93 42.8643.81 -2 PBT19.068.35 128 29.5530.78 -4 NP20.268.08 151 30.5330.40 0 Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Wanbury spurts after Tanuku facility clears ANVISA inspection with zero observations
The inspection was conducted from 16 December to 20 December 2024, confirmed the facility's strict adherence to Current Good Manufacturing Practices (cGMP). As a result, ANVISA has granted the facility the Good Manufacturing Practices (GMP) Certificate. Wanbury is a pharmaceutical company with a presence in the global API market and domestic branded formulations. The company's consolidated net profit declined 88.12% to Rs 1.22 crore as revenues fell by 8.28% to Rs 133.45 crore in Q3 FY25 as compared with Q3 FY24. Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Wanbury announces board meeting date
Wanbury will hold a meeting of the Board of Directors of the Company on 15 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Wanbury edges higher post conclusion of NCD refinancing at lower rates
The company stated that it has repurchased the entire Rs 95 crore issue of 21% secured NCDs, initially placed in July 2023 with NEO AIF and associates. This repurchase was facilitated through a Rs 175 crore debt refinancing from Emerging India Credit Opportunities Fund II (an associate of Investec Capital Services (India) Pvt. Ltd.). The refinancing offers a significantly reduced interest rate of 12.5% per annum on up to Rs 150 crore of existing debt, covering the Rs 90 crore owed to NEO AIF & associates and Rs 60 crore owed to other lenders. The remaining funds will be used for working capital and capital expenditure to support the company's growth. The repayment of this facility is structured over 5 years, with an average life of 3.25 years and a 9-month moratorium period. Mohan Rayana, whole-time director of Wanbury, said: We're pleased to announce the successful refinancing, underscoring our commitment to financial stability and growth. We're glad to announce the successful refinancing with Emerging India Credit Opportunities Fund II (an associate of Investec Capital Services (India) Pvt. Ltd.), resulting in significant savings in Interest cost. Wanbury is a pharmaceutical company with a presence in the global API market and domestic branded formulations. The company's consolidated net profit declined 88.12% to Rs 1.22 crore as revenues fell by 8.28% to Rs 133.45 crore in Q3 FY25 as compared with Q3 FY24. Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Wanbury consolidated net profit declines 88.12% in the December 2024 quarter
Net profit of Wanbury declined 88.12% to Rs 1.22 crore in the quarter ended December 2024 as against Rs 10.27 crore during the previous quarter ended December 2023. Sales declined 8.28% to Rs 133.45 crore in the quarter ended December 2024 as against Rs 145.50 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales133.45145.50 -8 OPM %10.4514.54 - PBDT4.6213.58 -66 PBT1.2910.26 -87 NP1.2210.27 -88 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Wanbury to declare Quarterly Results
Wanbury will hold a meeting of the Board of Directors of the Company on 12 February 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Wanbury to conduct EGM
Wanbury announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 20 February 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Wanbury consolidated net profit rises 8.97% in the September 2024 quarter
Net profit of Wanbury rose 8.97% to Rs 8.02 crore in the quarter ended September 2024 as against Rs 7.36 crore during the previous quarter ended September 2023. Sales rose 11.58% to Rs 161.19 crore in the quarter ended September 2024 as against Rs 144.46 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales161.19144.46 12 OPM %12.4112.00 - PBDT11.4910.43 10 PBT8.177.19 14 NP8.027.36 9 Powered by Capital Market - Live
7 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 8.56%, vs industry avg of 9.02%
Over the last 5 years, market share increased from 0.1% to 0.16%